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Abstract
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Lifestyle or age-related risk factors over-activate the inflammation that triggers acute heart failure
(HF)-related mortality following myocardial infarction (MI). Post-MI activated leukocytes express
formyl peptide receptor 2 (FPR2) that is essential for inflammation-resolution and in cardiac
healing. However, the role of FPR2 in acute HF is incomplete and remain of interest. Here, we
aimed to determine whether pharmacological inhibition of FPR2 perturb leukocyte trafficking in
acute HF. Male C57BL/6 (8 to 12 weeks) mice were subjected to acute HF (MI-d1) using
permanent coronary artery ligation that develops irreversible acute and chronic heart failure. FPR2
antagonist WRW4 (1μg/kg/day) was subcutaneously injected 3 hr post-MI maintaining salineinjected MI-controls. Leukocytes were quantitated using flow cytometry, and acute decompensated
HF was confirmed using echocardiography and histology. FPR2 inhibition decreased the
expression of FPR2 in the LV and spleen tissues. Administration of WRW4 inhibitor to mice
primed immature and inactive neutrophils infiltration Ly6Gint and intensified the Ccl2 expression
compared to MI-control in the infarcted LV post-MI. Leukocyte profiling revealed an overall
decrease in monocytes (23.3±2%) in WRW4-injected mice compared with MI-control (49.1±2%)
in infarcted LV. FPR2 inhibition increased F4/80+/Ly6Chi pro-inflammatory macrophages
(14.8±2%) compared with MI-control (10±1%) with increased transcripts of pro-inflammatory
markers TNF-α and IL-1β, and decreased Arg-1 expression in the infarcted LV compared to MIcontrols is suggestive of the impaired acute inflammatory response. Inhibition of FPR2 using
WRW4 also disturbed splenocardiac leukocytes recruitment by priming immature neutrophils
leading to the onset of incomplete resolution signaling in acute decompensated HF post-MI.
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Introduction
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After myocardial infarction (MI), acutely decompensated heart failure (HF) remains a
frequent cause of progressive chronic HF, disability, congestive edema, and death worldwide
(1). In acute HF, inflammation is a prerequisite for myocardial healing, but it can
paradoxically extend tissue injury if remain uncontrolled that lead to a pathological
remodeling process; hence it needs to be optimally balanced in acute HF. Therefore, for
optimal cardiac healing a synchrony between inflammation and resolution phase with
mature scar formation is necessary to return cardiac homeostasis that can lasts from few
days to weeks and encompasses the reparative phase. Therefore, leukocytes ‘get-in’ and
‘get-out’ signal has to be balanced that determines onset and termination of inflammation.
On time leukocytes activation with temporal and spatial inter-organ coordination between
injured heart and spleen during an inflammation-resolution phase is required for optimal
cardiac healing (2, 3).
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The G-protein–coupled formyl peptide receptors (FPRs) plays an important role in
controlled recruitment of immune cells to the site of injury (4). Mouse has a family of 8
FPRs, functionally FPR1 and FPR2 are present on immune cells and share a high degree of
amino acid sequence, showing similarity particularly at the cytosolic (signal transducing)
domains and the functional repertoire induced by these two receptors is almost identical.
Despite these signaling similarities, there are some fundamental differences between these
two receptors, that leads to different agonists that some of them bind specifically to FPR2 or
FPR1. Secondly, FPR1 plays a major role in anti-bacterial inflammation and metastasis of
malignant glioma cells while FPR2 interact with a number of endogenous chemotactic
agonist peptides produced by the host in defense and immune responses triggering both
proinflammatory and anti-inflammatory responses (5, 6). Since FPR2 serve as a ligand for
multiple bioactive lipids, peptides, and mediates proresolution by efficient coordination of
leukocytes in spleen and left ventricle (7, 8). FPR2 is also widely expressed on different cell
types and emerged as a central check point in inflammatory and resolving processes and
adaptive immunity although the precise role in acute HF is not well understood (9–11). In
the context of cardiac healing, the variable function of FPR2 is dependent on the nearby
bioactive lipids/peptides as available ligands, in a time-dependent manner (12). Neutrophilplatelet interaction and in-vitro peritonitis study emphasise the role of FPR2 in promoting an
inflammatory response (13, 14). However, a diversified function for FPR2 in non-resolving
inflammation relevant to the splenocardiac nexus in cardiac injury remains of interest. In
acute decompensated HF, particularly after occlusion of non-perfused cardiac injury, the
FPR2 is activated by bioactive lipids such as aspirin-triggered lipoxin A4, resolvin D1,
allowing a resolution of inflammation and return to homeostasis (7, 8).
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To determine how FPR2 inactivation impacts the initial acute inflammatory response in
acute HF, we pharmacologically blocked FPR2 using selective antagonist WRW4. We tested
whether FPR2 impedes leukocyte phenotypes and kinetics in acute decompensated HF. Our
findings revealed that FPR2 inhibition impaired leukocyte trafficking, by decreasing
leukocytes infiltrating in the infarcted LV and spleen. FPR2 antagonist WRW4 primed
immature and inactive neutrophils infiltration Ly6Gint that enhanced Ccl2 expression
compared to acute HF controls. Also, inhibition of FPR2 increased F4/80+/Ly6Chi, a set of
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pro-inflammatory macrophages in LV indicating amplified non-resolving milieu of innate
immune cells. After FPR2 inhibition using WRW4, the intensified pro-inflammatory
leukocytes were validated by an increase in TNF-α and IL-1β, with a decrease in Arg-1
expression suggestive of non-resolving or immune suppressive inflammation in acute HF.
Thus, the presented report suggests that, FPR2 inhibition using WRW4 distrupt leukocyte
‘get-in signal’ by engaging immature post-MI neutrophils leading to the onset of incomplete
resolution signaling in acute decompensated HF.

Methods
Animal care compliance
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All animal procedures were conducted according to the “Guide for the Care and Use of
Laboratory Animals” (8th Edition. 2011), AVMA Guidelines for the Euthanasia of Animals:
(2013 Edition) and were approved by the Institutional Animal Care and Use Committees at
the University of Alabama, Birmingham, USA.
Coronary ligation surgery and WRW4 injection
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C57BL/6J mice of 8–12 weeks old were obtained from Jackson Laboratory (Bar Harbor,
Maine, USA) and were maintained under constant temperature (19.8–22.2°C). The mice
were given free access to water and standard lab diet. Mice were subjected to permanent
coronary artery ligation as described previously (15). Vehicle or WRW4-(Trp-Arg-Trp-TrpTrp-Trp-NH2) (Torcis, catalog no. 557–55-2), is a selective antagonist for Formyl Peptide
Receptor 2 (FPR2) and was dissolved in PBS (1μg/kg/body weight) and injected
subcutaneously and then experiments were performed 24 hr post-MI. The mice were divided
into 3 groups- (1) Group-1 as a control group with no surgery (day 0: no-MI control), (2)
Group-2 as MI-saline group having MI surgery with vehicle treatment (MI-d1 post 24 hr),
(3) Group-3 was administered post MI 3 hr with WRW4 and evaluated 24hr post-MI (MId1+WRW4). To induce MI, mice were subjected to the surgical ligation of the left anterior
descending coronary artery. In brief, the mice were anesthetized with 2% isoflurane, and the
left anterior descending coronary artery was permanently ligated using nylon 8–0 sutures
(ARO Surgical Instruments Corporation, CA, USA) in minimally invasive surgery. Before
MI surgery buprenorphine (0.1 mg/kg; Intraperitonal (IP) and post-MI carprofen (5 mg/kg;
subcutaneous (SQ)) were administered to reduce pain (16).
Echocardiography
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For echocardiographic acquisition, mice were anesthetized using 1.5–2.0% isoflurane in a
100% oxygen mix. Images were acquired using the VEVO 3100 with probe MX400 and an
axial resolution of 30 μm in the vivo imaging system. Increased heart rates (heart rate > 400
beats per minute) were maintained during the acquisition to achieve physiological
measurements and short (M-mode), and long axis (B-mode) images of hearts were obtained
as discussed in our paper (15). Echocardiography was performed before necropsy for d0
control mice as well as MI-d1 control and post-MI-d1 WRW4-injected mice. Three images
were obtained for each variable from consecutive cardiac cycles. Ultrasound operator was
blinded to study groups to exclude bias in the comparison of MI-controls versus FPR2
inhibitor (15).
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No-MI naïve control (d0), MI-d1 control and post-MI-d1+WRW4 treated mice were
anesthetized under 2% isoflurane anesthesia in 100% oxygen mix. To collect plasma,
heparin (4 IU/g; I.P.) injection was used. The lungs and left and right ventricles were
collected, weighed and processed as previously described (15). The spleen was dissected by
making an incision in the left of the peritoneal wall. The spleen was divided into two halves,
and the broad and concave portion was fixed in 10% zinc formalin for IHC, and the rest of
the spleen was snap-frozen for biochemical and molecular analysis (8, 15).
LV histology and immunohistochemistry
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For histological measurements, left ventricle (LV) transverse and spleen sections were
embedded in paraffin and sectioned. Paraffin-embedded sections were de-paraffinized in
citrisolv and rehydrated through graded ethanol. Hematoxylin followed by eosin was used
for H&E staining. For neutrophil staining, the de-paraffinized sections are subjected to heatmediated antigen retrieval to expose antigen epitopes (Target Retrieval Solution, Dako
S1699) using a pressure cooker (BioSB Tinto Retriever). Sections were then blocked with
normal rabbit or goat serum as per antibody and incubated with rat anti-mouse neutrophils
(CL 8993AP, clone 7 1:50; Cedarlane). Neutrophils staining were followed with the
Vectastain Elite ABC kit (Vector). The slides were mounted using permount and allowed to
dry for use in image analysis (8).
LV confocal microscopy
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The de-paraffinized sections were fixed using 4% paraformaldehyde and. permeated using
0.1% Triton. The tissues were blocked for 1hr in 10% goat serum. Subsequently, tissues
were incubated with FPR2 (M-73) antibody (Santa Cruz, sc-66901) overnight. Alexa 555labeled anti-rabbit antibody (Molecular Probes, A21422) and Wheat germ agglutinin
(WGA) (W6748, 1:1000; Molecular. Probes) was added to sections for 60 min, followed by
Hoechst staining for 5 min. The stained sections were washed with PBS and mounted with
anti-fade and acquired using confocal microscopy (17).
Flow cytometry analysis for LV and spleen
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Single mononuclear cells were isolated from LV and spleen from post-MI-d1 control and
post-MI-d1 WRW4 and were analyzed by flow cytometry with slight modification (18). The
cell count for LV mononuclear cells or splenocytes was adjusted to ~1–2 million cells/stain.
Isolated cell suspensions were finally suspended in 200 μl of 1:500 Fc block and incubated
for 10 min on ice. The LIVE/DEAD™ Fixable Blue Dead Cell Stain Kit (Thermo Fischer
Scientific, L34961) is used to determine the viability of cells before the fixation. A cocktail
of fluorophore-labeled monoclonal antibodies in 2X concentration was added for 30 min on
ice as appropriate for each study. We used CD45-PE (BD Biosciences,103114), CD11b-APC
(BD Biosciences, 553312) F4/80-Percp (Thermo Fischer Scientific, 45–4801-821), Ly6CFITC (BD Biosciences), Ly6G-pacific blue (BioLegend, 127612) in a cocktail. All
population is primarily gated using CD45+ markers for hematopoietic cells. Further, the
neutrophils were defined as CD11b+/Ly6G+cells. Activated macrophages were defined as
the cells having dual expression CD11b and F4/80 surface marker. The macrophages
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(F4/80+) were also classified as M1 (classically activated macro-phages) and M2
(alternatively activated macrophages) based on Ly6Chi and Ly6Clo respectively. Detailed
gating strategy is provided in supplementary figure 1. Data were acquired on BDTM LSRII
Flow Cytometer and analyzed with FlowJo software, version 7.6.3 as described previously
(19).
RNA isolation and quantitative real time-PCR
Post-necropsy, samples were processed for RNA extraction as described previously (8). For
qPCR, reverse transcription was performed with 2.0 μg of total RNA from LV using
SuperScript® VILO cDNA Synthesis kit (Invitrogen, CA, USA). Quantitative PCR for the
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FPR2 (Mm00484464)), Ccl2 (Mm00441242), Ptgs1(Mm00477214_m1), Ptgs-2
(Mm00478374_m1), Alox12 (Mm00478374_m1), Alox15 (Mm00507789_m1), Alox5
(Mm01182747_m1), Tnf-α (Mm00443258), IL-1β (Mm00434228), Il10 (Mm01329362),
Mrc1 (Mm01288386), Arg1(Mm00475988), and Ym1(Mm00657889) genes were
performed using TaqMan probes, as done previously.(20) Gene expression was normalized
with hypoxanthine phosphoribosyltransferase-1 (Hprt-1) (Mm03024075_m1) as the
housekeeping gene. The results were reported as 2^−ΔCT. All the experiments were
performed in duplicate with n= 5–6 per group (19).
Statistical analysis
Data are expressed as mean per group and SEM. Statistical analyses were performed using
GraphPad Prism 7. Analysis of variance (ANOVA), followed by Newman–Keuls post-hoc
test, was done for multiple comparisons between no-MI naïve control, MI-d1 control, MI
+WRW4.
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Results
Coronary ligation induced cardiac injury with profound pathological remodeling
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The current study was designed to evaluate how FPR2 inhibition impacted leukocyte ‘get-in’
signal post-MI (Figure 1A). To determine the impact of WRW4 on FPR2 signaling in acute
HF post-MI, the LV function was measured using echocardiography. The ultrasound images
of heart were acquired in no-MI naïve control, MI-control (MI-d1; 24h) and MI+WRW4injected mice. Speckle tracking-based blinded analyses revealed that MI-control mice and
MI+WRW4 had impaired strain (short green vector) with intense cardiac dysfunction from
remote anterior base compared with no-MI naive control. Representative M-mode images
confirm the loss of posterior wall thickness suggestive of anterolateral infarct and LV
dysfunction due to coronary ligation in MI-control and MI+WRW4 mice (Figure 1B).
Echocardiography data displayed a decrease in fractional shortening (Figure 1C and Table 1
A) in MI-control (8±1%), MI+WRW4 (8±1%) compared with no-MI control mice
(36.1±1.6%). Hematoxylin and eosin staining of LV in MI-control and MI+WRW4 mice
showed obvious necrosis and disorganized structure in the infarcted area compared with noMI control mice with notable changes in gravimetric parameters (Figure 1D and Table 1B).
Our results confirmed that the coronary ligation in mice induced profound cardiac
dysfunction in MI-control and MI+WRW4 treated mice suggestive of acute decompensated
HF.
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FPR2 inhibition using WRW4 upregulated monocyte marker CCL2 along with LOXs and
COX-1 post-MI
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Since, FPR2 plays and important role in both innate and adaptive response, we further
examined how FPR2 inhibition would impact chemotactic response to leukocytes after
cardiac injury. FPR2, is a competitive receptor that is also activated by bioactive lipid
biomolecule to offer cardio-protection with clearance of neutrophils (7). Here, first, we
validated whether 1μg/kg dose is enough to inhibit FPR2. For this, we measured mRNA and
did immunofluorescence to validate FPR2 inhibition post-MI (Figure 2A and B). Increase in
chemotactic response in LV post-MI is an obvious phenomenon due to cardiac injury.
However, an increased chemotactic response to the chemokine CCL2 was observed in LV
infarct of MI+WRW4 mice (Figure 2C). The cardiac healing using FPR2 bioactive ligand
molecules is essential in response to cardiac injury or infection (7, 8, 21). We further
validated how FPR2 inhibition would impact FPR2 ligand biosynthesizing enzymes such as
cyclooxygenase (COX) and lipoxygenase (LOXs) that uses arachidonic acid as a substrate.
Thus, we analyzed the LV mRNA expression of the COXs (−1 and −2) and LOXs (−15, −12
and-5). Post-MI, WRW4 treatment differentially impacted COX-1 and COX-2 in LV infarct.
WRW4 increased COX-1 expression (1.5 fold; p<0.05) while decreased in COX-2
expression was observed (−10 fold, p<0.05) compared with MI-control in acute HF (Figure
2D and E). WRW4 increased LV mRNA expression of Alox12 (2.7 fold; p<0.05), Alox15
(7.7 fold; p<0.05) and Alox5 (12.9 fold; p<0.05) post-MI compare with MI-control (Figure.
2F–H). These results indicate that FPR2 inhibition increased LV chemotaxis rendering over
activated CCL2 response post-MI, which may result in a feed-forward uncontrolled increase
in COX-1 and LOXs expression, in LV post-MI.
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FPR2 inhibition using WRW4 activated pro-inflammatory macrophages in the infarcted LV
post-MI

Author Manuscript

Splenic neutrophils and monocytes infiltrate heart post-MI in the infarcted area to facilitate
healing and myocardium (2). We applied quantitative flow cytometry-based approach that
defined the impact of FPR2 inhibition on leukocyte profiling in LV and spleen post-MI in
acute HF. After mononuclear cell isolation, the cell viability was assessed by using LIVE/
DEAD™ - fixable blue dead cell stain kit. WRW4 injected mice demonstrated a significant
decrease in CD45+CD11b+ (monocytes) cells in LV (23.3±2%) and spleen (3.8±0.5%)
compared with MI-control which showed 49.1±2% and 10±1.3% population respectively
(Figure. 3A–B). Total population of macrophages (F4/80+) was decreased in WRW4injected mice in spleen (0.45 ±0.2% vs 7.8 ±1%) and LV (17±1% vs 38.6 ± 2%) compared
to MI-control (Figure. 3C–D). Despite the decrease in total macrophages in LV, FPR2
inhibition using WRW4 showed increase in macrophages percentage F4/80+/Ly6Chi
(14.8±2%) in LV indicative of proinflammatory leukocyte profile compared with MI-control
(10±1%) (Figure. 3E–F). Thus, FPR2 inhibition impaired leukocyte trafficking (‘get-in’
signal) by decreasing the density of infiltrating leukocytes in the spleen and infarcted LV in
acute HF post-MI.
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FPR2 inhibition using WRW4 primed immature and inactive neutrophils infiltration
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Neutrophils are first phagocytic non-specific responder at the site of cardiac injury and
respond to diverse chemo attractants including FPR2 receptor and leukotrienes (22).
Intriguingly, flowcytometry-based quantitation of leukocytes from spleen and LV displayed
lower neutrophils in the spleen of WRW4-injected mice (2.4±0.3%) compared with MIcontrol (5.1±0.3%) in acute HF. However, there was no difference observed in percentage of
neutrophils population in the LV. Interestingly, LV revealed two types of the Ly6G
population; MI-control group displayed Ly6Ghi while WRW4 treated group exhibited a
Ly6G population having intermittent expression termed as Ly6Gint neutrophils (Figure 4A–
D). Studies have reported that immature neutrophils express intermediate Ly6G levels which
are inactive and dysfunctional (23). Thus, WRW4-mediated FPR2 inhibition primed
immature and inactive neutrophils in cardiac injury leading to non-resolving inflammation.
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WRW4-mediated FPR2 inhibition dysregulated cytokine-chemokine kinetics post-MI in
acute HF
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Since, FPR2 inhibition using WRW4 decreased over all leukocytes and activated immature
neutrophils in acute HF, we quantified mRNA levels of chemokines markers
(proinflammatory and proresolving) TNF-α, IL-6, IL-10, Mrc-1/CD206, Arg-1, and Ym-1.
Administration of WRW4 in acute HF increased transcripts of pro-inflammatory markers
TNF-α and IL-1β indicative of non-resolving or amplified acute inflammation. However, we
also observed potential increase in Arg1, IL-10, and Ym-1 (p<0.05) in infarcted LV of
WRW4-injected mice compared to MI-controls with no change in MRC-1/CD206
expression. These results indicated an imbalance of pro-inflammatory and pro-resolving
cytokines-chemokines expression suggestive of dysregulated innate response by FPR2
inhibition in acute HF.

Discussion
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Chronic and non-resolving inflammation is a critical component in the progression of HF
post-MI. In response to cardiac injury splenic leukocytes, diversity plays a critical role in
resolution of post-MI inflammation (2). On time, activated leukocytes ‘arrival’ or ‘get-in
signal’ and ‘departure’ or ‘get-out’ signal is essential post-MI cardiac healing (24). Formyl
peptide receptor 2 (FPR2), is known to mediate both pro-resolving and inflammatory
responses by modulating myeloid cells kinetics in multiple organs including lacrimal and
salivary glands by binding to the respective receptors (9, 25, 26). Our previous studies
defined that proresolving RvD1 and 15-epi-LXA4 ligands activates FPR2 in order to resolve
inflammation in cardiac healing post-MI (7, 8). The current report investigated how FPR2
inhibition impacted ‘get-in’ signals of leukocytes in acute HF. Our study defined the critical
role of FPR2 in acute HF since the post-MI inhibition; 1) primed immature and inactive
neutrophils (Ly6Gint) infiltration (over activated ‘get-in’ signal); 2) depleted over all
leukocytes population in LV and spleen; 3) increased F4/80+/Ly6Chi pro-inflammatory
macrophages in acute HF (delayed ‘get-out signal’). Thus, inhibition of FPR2 altered
leukocyte ‘get-in’ signal thereby eliciting a non-resolving response in acute HF post-MI.
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Cells producing chemokines act on chemokine receptors (mostly GPCRs) and initiate a
chemotactic response which is required to initiate an acute inflammatory response in HF
essential for cardiac healing (27). The chemotactic response depends on the number of
chemokines produced and their gradient and also on the expression levels of their receptors
(28). FPR2 is a chemoattractant GPCR, expressed by human monocytes/macrophages and
neutrophil and is stimulated by lipids and peptides (29, 30). FPR2 is a dual-edge sword and
its activation can either lead to pro-inflammatory or proresolving response (31). FPR2 is
activated in response to cardiac injuries such as MI and both spleen and LV coordinate to
resolve inflammation (15). After cardiac injury, neutrophils are the first key responders (32,
33), this FPR2 being competitive receptor is highly expressed in the splenic leukocytes
including neutrophils compared with LV in acute HF. After cardiac injury, splenic monocyte/
macrophages and neutrophils are vital for clearing the debris and interact with macrophages
to resolve inflammation to return tissue to homeostasis. The inhibition of FPR2, using the
WRW4 enhanced the unaltered neutrophil response in acute HF indicating no change in
neutrophil population. However, the neutrophils appeared to be immature revealing Ly6Gint
expression indicative of impaired of ‘get-in’ signal that altered or delayed initiation of the
acute inflammatory response. Deniset et al. discovered that immediate presence of
neutrophils in spleen help to eradicate infection carrying bacteria and with a possibility that
the circulating neutrophils that enter the red pulp to mature and perform a necessary function
indicating that neutrophil presence in the spleen are critical for innate immune response;
likewise dysfunctional FPR2 aggravate sepsis and myocardial dysfunction (21, 23). Our
study outcome aligns with former reports, indicating the presence of immature neutrophils
blunting ‘get-in’ signal of leukocytes. A recent study in FPR2 null mice demonstrated that
Fpr2 is required for SCF/c-Kit-mediated Linc-Kit+Sca-1+ cell proliferation indicating an
FPR2 role for the development of myeloid lineage (9). Thus, our study using a
pharmacological inhibitor of FPR2 highlighted the critical role of FPR2 in leukocytes
activation and redirecting neutrophils toward the site of injury in acute HF.
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The absence of FPR2 promotes chronic inflammation that impacts neutrophil response and
maturation (34). FPR2 is also essential in myeloid cell development and mediating leukocyte
recruitment (10). In contrast, our study has shown that FPR2 inhibition intensified CCL2,
which is a signal for enhanced leukocytes mobilization but we observed overall decrease in
monocytes and macrophages in acute HF which indicated initiation failure of innate immune
response. FPRs are ubiquitously expressed, but FPR2 inhibition decreased overall
leukocytes, and neutrophils antecede monocyte/macrophage in acute HF indicated FPR2
control leukocyte kinetics in acute HF (32). FPR2 inactivation increased proinflammatory
(F4/80+/Ly6Chi) macrophage infiltration which can be correlated with the gain in the
chemokine CCL2. FPR2 can impact both pro-inflammatory and pro-resolving response
depending up on the agonist (7, 8, 35, 36). Thus, FPR agonist/antagonist dependent
activation of polarized macrophages that explain the leukocyte phenotype heterogeneity. Our
study has provided evidence that inhibition of FPR2 using WRW4 boosted proinflammatory markers TNF-α and IL-6 with a compensatory increase in Arg-1, IL-10, and
Ym-1 in acute HF indicative of overactivated inflammatory microenvironment. Initiation of
the acute inflammatory response is essential for cardiac healing in an optimal manner (2,
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15), but FPR2 inhibition led to an imbalance of chemokine signaling which failed to activate
a required initial inflammatory response in acute HF.
Our study provided a critical insight with FPR2 inactivation that delayed initiation of
splenocardiac acute inflammatory response which is mandatory for cardiac healing. Thus,
FPR2 play agonist/antagonist dependent switch controlling the ‘get-in’ signal in acute HF. In
summary, our results revealed evidence that timely activation of FPR2 is important to
resolve post-MI inflammation. Pharmacological inhibition of FPR2 alters ‘get-in’ signaling
of leukocyte leading to non-resolving inflammation in acute HF. Our study has a limitation
that we used a single dose of FPR2 antagonist WRW4 to inactivate FPR2 for 24 hr,
moreover the LV dysfunction difference was insignificant. Thus, long-term studies are
warranted to precisely monitor leukocyte ‘get-in’ and ‘get-out’ signal and phenotypic
leukocyte polarization in context of FPR2 signaling.
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Figure 1. FPR2-antagonist WRW4 leads to LV dysfunction post-MI.

A. An experimental design indicating WRW4 injection strategy in coronary artery ligation
model with time points. B. Speckle tracking-based LV function analyses using
echocardiography. C. Bar graph representing percentage fractional shortening at d1 in MIcontrol and WRW4-injected mice post-MI compared to no-MI naïve controls. D.
Hematoxylin and eosin images of no-MI, MI-control, and MI+WRW4-injected mice LV
(remote area, peri-infarct, and infarct) post-MI. Images are taken at 40X; scale=50μM.
*p<0.05 vs no-MI controls; values are means ±SEM; n=6–8 mice/group.
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Figure 2. WRW4 upregulated monocyte marker ccl2 along with LOXs with COX-1 post-MI.

A. Bar graph representing mRNA expression of FPR2 normalized with HPRT-1 in LV. B.
representative LV images indicating FPR2 (red) expression with wheat germ agglutinin
(WGA) and hoechst (blue) from MI-control and MI+RvD1-injected mice (scale bars: 20
μm). Bar graph representing mRNA expression of C. CCL2 D. COX-1 E. COX-2 F.
ALOX12 G. ALOX15 H. ALOX5 in LV normalized with HPRT-1. *p<0.05 versus no-MI.
$p < 0.05 versus post MI-D1 group. Values are means ±SEM; n=5 mice/group.
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Figure 3. FPR2 inhibition using WRW4 activated F4/80+/Ly6Chi in the infarcted LV with a
decrease in CD11b+ and F4/80+ population post-MI.

A. Representative FACs counter plots are identifying spleen and LV CD45+/CD11b
in MI+WRW4–injected mice compared with MI-control mice. B. Bar graph
displaying CD45+/CD11b+ population in spleen and LV. C. Representative counter plots
showing CD45+/CD11b+/F4/80+population in spleen and LV in MI+WRW4-injected mice
compared with no-MI control. D. Bar graph displaying CD45+/CD11b+/F4/80+population in
spleen and LV. E. Representative FACs counter plots identifying spleen and LV CD45+/
CD11b+/F4/80+/Ly6C population in MI+WRW4–injected mice compared with MI-control
mice. F. Bar graph displaying CD45+/CD11b+/F4/80+/Ly6Chi population in spleen and LV.
*p<0.05 versus spleen; $ p<0.05 respective-MI-control. Values are means ±SEM; n=4 mice/
group.
+population
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Figure 4. WRW4 dysregulated neutrophils clearance post-MI.

A. Representative flow cytometry (FACs) counterplots showing spleen and LV neutrophils
population (CD45+/CD11b+/F4/80−/Ly6G+) population in MI-control and MI+WRW4injected mice post-MI. B. Representative spleen and LV FACs histogram displaying Ly6G
expression. C. Bar graphs shows percentage of Ly6G+ population in LV and spleen post-MI.
D. Representative neutrophil immunohistochemistry images of LV transverse section of MIcontrol and WRW4-injected mice post-MI (Magnification 40X, scale = 50 μm). *p<0.05 vs
spleen; $ p<0.05 respective MI-control. Values are means ±SEM; n=4 mice/group.
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Figure 5. WRW4 modulated chemokine kinetics post-MI in acute HF.

A. Bar graph representing mRNA expression of A. Tnf-α, IL-1β, and IL-10 B. Mrc-1, Arg-1
and Ym-1 in LV-infarct post-MI. C. Schematic representation of inflammation-resolution
axis depicting the role of WRW4 and non-resolving mechanism in acute HF. *p<0.05 versus
no-MI control post-MI. Values are means ±SEM; n=4 mice/group.
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Echocardiography and necropsy parameters at day 1 post-MI compared to naïve controls (no-MI).
Parameters

No-MI control (n=8)

MI-day 1 (n=10)

MI-day 1+WRW4 (n=10)

446±12

481±17

540±10*

EDD (mm)

3.61±0.07

4.64±0.10*

4.67±0.08*

ESD (mm)

2.31±0.10

4.33±0.11*

4.28±0.08*

36±2

8 ±1*

8±1*

PWTd (mm)

0.66±0.04

0.48±0.02*

0.55±0.03*

PWTs (mm)

1.09±0.03

0.52±0.02*

0.64±0.03*

Body weight (g)

26±1

24±1

26±0.4

LV (mg)

80±3

88±2

91±2*

3.2±0.1

3.7±0.1*

3.5±0.1*

Right ventricle (mg)

20±1

21±1

21±1

Spleen (mg)

77±5

61±4*

71±3*$

LV / Tibia (mg/mm)

4.8±0.2

5.2±0.1*

5.2±0.1*

Tibia (mm)

17±0.1

17±0.1

17±0.1

Heart rate (bpm)

Fractional shortening (%)

$

$

Necropsy parameters

Author Manuscript

LV/BW (mg/g)

Values are mean± SEM; n indicates sample size. bpm, beats per minute; EDD, end-diastolic dimension; ESD, end-systolic dimension, mm,
millimeter; g, gram; mg, milligram

*

p< 0.05 vs. No-MI control

$

p< 0.05 vs. MI-d1 control with respective time point.
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